Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a more favorable profile regarding sedation, though tolerance and dependence remain relevant clinical issues.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS). Off-label use includes refractory focal or generalized epilepsy.
## Adult Dosing
* **Initial:** 10 mg/day (given in 2 divided doses).
* **Titration:** Increase at weekly intervals as tolerated.
* **Target Dosage:** 20 mg/day.
* **Maximum Dosage:** 40 mg/day (administered in 2 divided doses).
## Pediatric Dosing (≥2 years)
Dosage is weight-based for patients weighing ≤30 kg:
* **Initial:** 5 mg/day.
* **Target Dosage:** 10 mg/day.
* **Maximum Dosage:** 20 mg/day.
For patients >30 kg, use adult dosing guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Requires dose reduction. Use 50% of the recommended initial dose; titrate with extreme caution.
* **Renal Impairment:** No specific criteria exist, but caution is advised.
* **CYP2C19 Poor Metabolizers:** Clobazam levels may increase significantly. Start at 50% of the recommended dose and titrate cautiously.
## Contraindications
Documented hypersensitivity to clobazam or any components of the formulation.
## Adverse Effects
* **Common:** Somnolence, pyrexia, lethargy, drooling (sialorrhea), constipation, and upper respiratory tract infections.
* **Serious:** Risk of severe skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis), respiratory depression, and paradoxical reactions (aggression/irritability).
## Key Drug Interactions
* **CYP2C19 Inducers/Inhibitors:** Inhibitors (e.g., fluconazole, fluvoxamine) significantly increase levels of the active metabolite, *N*-desmethylclobazam.
* **CNS Depressants:** Combined use with opioids or alcohol markedly increases the risk of profound sedation, respiratory depression, coma, and death.
* **Valproate:** May increase serum concentrations of the active metabolite.
## Monitoring
* **Baseline/Ongoing:** Monitor for excessive sedation, behavioral changes, and signs of respiratory compromise.
* **Dermatologic:** Observe for skin rashes; discontinue immediately if SJS/TEN is suspected.
* **Withdrawal:** If stopping, taper slowly to prevent status epilepticus or benzodiazepine withdrawal symptoms.
## Clinical Pearls
* **Metabolism:** Clobazam is primarily metabolized by CYP3A4 and CYP2C19 to *N*-desmethylclobazam, which has 1/5 to 1/20 the anticonvulsant potency of the parent drug but higher systemic exposure.
* **Administration:** Oral suspension and tablets may be administered without regard to food. The oral suspension must be used within 90 days of first opening the bottle.
* **Abuse Potential:** Classified as a Schedule IV controlled substance.
* **Clinical Uncertainty:** Exact dosing for off-label indications varies by clinical institution; local neurology protocols should be consulted for status epilepticus or acute seizure management scenarios.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing guidelines and contraindications are subject to change. Always verify current prescribing information via institutional protocols, official FDA-approved labels, or clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
